The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01809574 |
Recruitment Status
: Unknown
Verified October 2013 by Meir Medical Center.
Recruitment status was: Recruiting
First Posted
: March 12, 2013
Last Update Posted
: April 9, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Interstitial Lung Disease Idiopathic Pulmonary Fibrosis Connective Tissue Disease |
Study Type : | Observational |
Estimated Enrollment : | 60 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease |
Study Start Date : | May 2013 |
Estimated Primary Completion Date : | March 2016 |
Estimated Study Completion Date : | March 2016 |

- The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists. [ Time Frame: two years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age above 18 years old
- ILD according to ATS/ERS guidelines
- Signed inform consent
Exclusion Criteria:
- Previous lung surgery
- Other significant systemic disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01809574
Contact: David Shitrit, Dr. | 097471556 | davids3@clalit.org.il |
Israel | |
Meir Medical Center | Recruiting |
Kfar Saba, Israel, 972 | |
Contact: David Shitrit, Dr 09-7471556 davids3@clalit.org.il |
Principal Investigator: | David Shitrit, Dr | Head of Pulmonary departmant, Meir Medical Center. |
Responsible Party: | Meir Medical Center |
ClinicalTrials.gov Identifier: | NCT01809574 History of Changes |
Other Study ID Numbers: |
225-12-MMC |
First Posted: | March 12, 2013 Key Record Dates |
Last Update Posted: | April 9, 2015 |
Last Verified: | October 2013 |
Keywords provided by Meir Medical Center:
Interstitial lung disease Idiopathic pulmonary fibrosis Connective tissue disease |
Additional relevant MeSH terms:
Fibrosis Lung Diseases Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Interstitial Pneumonias |
Lung Diseases, Interstitial Connective Tissue Diseases Pathologic Processes Respiratory Tract Diseases |